Although these findings indicated that blocking LT-α may be of potential benefit in specific population of patients with RA who do not respond to anti-TNF-α therapy or develop resistance to such therapy, they should be further verified with experimental model or clinical data. The gene discussed is LTA; the disease is rheumatoid arthritis.